Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.

13. juni 2026 oppdatert av: Ming Liu

A Multicenter, Single-Arm, Phase II Study of Mannatide Combined With CAPOX and Tislelizumab as First-Line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.

This is a multicenter, open-label, single-arm phase II study evaluating the efficacy and safety of mannatide in combination with CAPOX chemotherapy and tislelizumab as first-line treatment for patients with recurrent or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

Eligible patients will receive oxaliplatin, capecitabine, tislelizumab, and oral mannatide. Tumor response will be assessed according to RECIST version 1.1. Patients without disease progression after induction treatment may continue maintenance therapy with capecitabine, tislelizumab, and mannatide.

The primary objective is to evaluate objective response rate (ORR). Secondary objectives include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), and safety. Exploratory analyses will investigate immune microenvironment changes and potential predictive biomarkers using blood, tumor tissue, and stool samples.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Gastric cancer remains one of the leading causes of cancer-related mortality worldwide. Although immune checkpoint inhibitors combined with chemotherapy have improved outcomes in advanced gastric and gastroesophageal junction adenocarcinoma, many patients still fail to achieve durable responses.

Mannatide is an immunomodulatory agent that has been shown to enhance both innate and adaptive immune responses. Preclinical and clinical studies suggest that mannatide may improve antitumor immunity through activation of macrophages, enhancement of antigen presentation, stimulation of T-cell proliferation, and promotion of natural killer cell activity. These properties provide a rationale for combining mannatide with chemotherapy and immune checkpoint blockade.

This study is a multicenter, open-label, single-arm phase II trial enrolling approximately 52 patients with unresectable recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Participants will receive CAPOX chemotherapy (oxaliplatin plus capecitabine), tislelizumab, and oral mannatide as first-line treatment.

Treatment will be administered for six induction cycles. Tumor assessments will be performed every two cycles according to RECIST version 1.1. Patients without disease progression may continue maintenance therapy consisting of capecitabine, tislelizumab, and mannatide until disease progression, unacceptable toxicity, withdrawal of consent, initiation of another anticancer therapy, death, or completion of the maximum treatment duration.

The primary endpoint is objective response rate (ORR). Secondary endpoints include progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DoR), and safety. Exploratory endpoints include single-cell RNA sequencing, single-cell T-cell receptor sequencing, multiplex immunofluorescence analysis, and gut microbiome profiling to identify biomarkers associated with treatment response.

Studietype

Intervensjonell

Registrering (Antatt)

52

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Kina
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • West China Hospital of Sichuan University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, including signet ring cell carcinoma, mucinous adenocarcinoma, and hepatoid adenocarcinoma.
  2. Unresectable recurrent or metastatic disease confirmed by imaging and surgical evaluation.
  3. Age 18 to 75 years.
  4. Expected survival greater than 3 months.
  5. No prior systemic therapy for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma. Previous neoadjuvant or adjuvant therapy is allowed if completed at least 6 months before enrollment without evidence of recurrence or progression.
  6. ECOG performance status 0-1.
  7. At least one measurable lesion according to RECIST version 1.1.
  8. Availability of tumor tissue for PD-L1 testing.
  9. Adequate hematologic, hepatic, renal, and coagulation function.
  10. Recovery of prior treatment-related toxicities to Grade 0-1 or baseline level.
  11. Negative pregnancy test for women of childbearing potential and agreement to use effective contraception.
  12. Ability to understand and willingness to sign informed consent.

Exclusion Criteria:

  1. HER2-positive gastric or gastroesophageal junction adenocarcinoma.
  2. Squamous cell carcinoma, undifferentiated carcinoma, or mixed histology.
  3. Active or uncontrolled central nervous system metastases.
  4. Uncontrolled pleural effusion, ascites, or clinically significant pericardial effusion.
  5. Weight loss greater than 20% within 2 months before enrollment.
  6. Major surgery within 28 days before enrollment.
  7. Prior anti-PD-1, anti-PD-L1, anti-CTLA-4, or other immune checkpoint inhibitor therapy.
  8. Active autoimmune disease requiring systemic treatment.
  9. Active hepatitis B, hepatitis C, or HIV infection.
  10. Interstitial lung disease or uncontrolled systemic disease.
  11. Significant cardiovascular disease within 6 months before enrollment.
  12. Known hypersensitivity to study drugs or their components.
  13. Participation in another interventional clinical trial within 4 weeks before enrollment.
  14. History of substance abuse or severe psychiatric disorder.
  15. History of rheumatic heart disease or known hypersensitivity to mannatide.
  16. Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study evaluation.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CAPOX + Tislelizumab + Mannatide
Participants will receive CAPOX chemotherapy (oxaliplatin and capecitabine), tislelizumab, and oral mannatide as first-line treatment for recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
Legemiddel: Oxaliplatin
Oxaliplatin 130 mg/m² administered intravenously on Day 1 of each 21-day treatment cycle as part of the CAPOX regimen.
Legemiddel: Capecitabine
Capecitabine 1000 mg/m² orally twice daily on Days 1-14 of each 21-day treatment cycle.
Legemiddel: Tislelizumab
Tislelizumab 200 mg administered intravenously on Day 1 of each 21-day treatment cycle.
Legemiddel: Mannatide
Mannatide 10 mg administered orally three times daily throughout study treatment.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Objective Response Rate (ORR)
Tidsramme: From treatment initiation until disease progression, assessed every 6 weeks during induction treatment and every 6 to 8 weeks during maintenance treatment, up to 24 months.
Objective response rate defined as the proportion of participants achieving a complete response (CR) or partial response (PR) according to RECIST version 1.1.
From treatment initiation until disease progression, assessed every 6 weeks during induction treatment and every 6 to 8 weeks during maintenance treatment, up to 24 months.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total overlevelse (OS)
Tidsramme: Inntil 24 måneder
Inntil 24 måneder
Disease Control Rate (DCR)
Tidsramme: Inntil 24 måneder
Inntil 24 måneder
Duration of Response (DoR)
Tidsramme: Up to 24 months
Up to 24 months
Incidence of Adverse Events
Tidsramme: From first dose through 30 days after the last dose, up to 24 months.
Adverse events assessed according to NCI CTCAE version 5.0.
From first dose through 30 days after the last dose, up to 24 months.
Quality of Life (QoL)
Tidsramme: Baseline through completion of study treatment, up to 24 months.
Quality of life assessed using the EORTC QLQ-C30 questionnaire.
Baseline through completion of study treatment, up to 24 months.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Ming Liu

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. juli 2026

Primær fullføring (Antatt)

1. juli 2028

Studiet fullført (Antatt)

1. juli 2029

Datoer for studieregistrering

Først innsendt

13. juni 2026

Først innsendt som oppfylte QC-kriteriene

13. juni 2026

Først lagt ut (Faktiske)

18. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. juni 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. juni 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 2025 Review (2538)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere